研发开支大增123% 迈博药业-B(02181.HK)中期亏损扩大168.4%至1.16亿元
格隆汇8月30日丨迈博药业-B(02181.HK)公布,截至2019年6月30日止6个月,公司其他收入372.6万元人民币,同比减少63.4%;期间亏损1.16亿元,亏损同比扩大168.4%;每股亏损0.03元。
收入减少主要是因为本报告期间没有任何提供制备工艺服务的收入,因为公司全力研发自有产品,停止向其他公司提供制备工艺服务。
公司是中国领先的生物医药公司,专注于治疗癌症和自身免疫性疾病的新药及生物类似药的研发和生产。公司致力于透过高效的研发体系以及低成本药品生产能力为市场带来高质量且可负担的创新型生物药品,并充分利用自身丰富的研发经验开发多种治疗产品。公司的候选药物管线目前包括9种单克隆抗体药物,其中3种为处于III期临床试验的核心产品:CMAB007(奥马珠单抗)、CMAB009(西妥昔单抗)和CMAB008(英夫利昔单抗)。公司其他候选药物中,CMAB809(曲妥珠单抗)已经启动I期临床试验,CMAB819(纳武单抗)即将启动临床试验。
公司认为定能把握中国巨大的市场机遇,特别是中国近期的医疗监管改革(包括新医保措施)带来的机遇。公司研发的主要重心为针对癌症和自身免疫性疾病的单克隆抗体药物,该药物在中国具有庞大未开发的临床需求。
期间本集团的在研药物研发开支由上年同期的人民币26.3百万元增加123.0%至人民币58.7百万元,主要是随着临床试验进度的深入,相应的临床试验费用、人员费用以及设备折旧的增加。
公司的银行结余及现金由2018年12月31日的人民币198.2百万元增加至2019年6月30日的人民币1,009.4百万元,银行结余及现金增加了人民币811.2百万元,其由于公司股份于在联交所上市,全球发售所得款项净额约为1,144.5百万港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.